Hemispherx BioPharma Company Profile (NYSE:HEB)

About Hemispherx BioPharma

Hemispherx BioPharma logoHemispherx Biopharma, Inc. (Hemispherx) is a specialty pharmaceutical company engaged in the clinical development of new drugs therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. The Company's flagship products include Alferon N Injection and Ampligen. Alferon N Injection is approved for the use in intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older. Ampligen is an experimental drug undergoing clinical development for the treatment of CFS (Chronic Fatigue Syndrome). The Company's Alferon LDO (Low Dose Oral) is an experimental liquid natural interferon for oral administration.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: NYSE
  • Symbol: HEB
  • CUSIP:
Key Metrics:
  • Previous Close: $1.94
  • 50 Day Moving Average: $1.79
  • 200 Day Moving Average: $1.63
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $482.93M
  • Outstanding Shares: 248,932,000
Additional Links:
Companies Related to Hemispherx BioPharma:

Analyst Ratings

Consensus Ratings for Hemispherx BioPharma (NYSE:HEB) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Hemispherx BioPharma (NYSE:HEB)
Show:
DateFirmActionRatingPrice TargetDetails
4/2/2015Midtown PartnersInitiated CoverageStrong-Buy$1.45View Rating Details
(Data available from 8/30/2014 forward)

Earnings

Earnings History for Hemispherx BioPharma (NYSE:HEB)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/9/2015        
8/15/2016Q216($0.01)ViewN/AView Earnings Details
5/16/2016Q116($0.01)$40.99 millionViewN/AView Earnings Details
8/13/2015Q2($0.02)ViewN/AView Earnings Details
5/13/2015Q1 15($0.02)ViewN/AView Earnings Details
8/9/2013Q2 2013($0.03)ViewN/AView Earnings Details
11/5/2012Q312($0.04)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Hemispherx BioPharma (NYSE:HEB)
Current Year EPS Consensus Estimate: $0.00 EPS
Next Year EPS Consensus Estimate: $-0.03 EPS

Dividends

Dividend History for Hemispherx BioPharma (NYSE:HEB)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Hemispherx BioPharma (NYSE:HEB)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/8/2016Thomas K EquelsCEOBuy48,000$0.12$5,760.00View SEC Filing  
7/1/2016Thomas K EquelsCEOBuy171,000$0.12$20,520.00View SEC Filing  
3/18/2016Thomas K EquelsCEOBuy30,000$0.13$3,900.00View SEC Filing  
3/11/2016Thomas K EquelsCEOBuy40,000$0.16$6,400.00View SEC Filing  
3/10/2016Thomas K EquelsCEOBuy30,000$0.16$4,800.00View SEC Filing  
8/20/2015William A CarterCEOBuy25,000$0.18$4,500.00View SEC Filing  
8/18/2015William A CarterCEOBuy25,000$0.18$4,500.00View SEC Filing  
8/17/2015William A CarterCEOBuy25,000$0.18$4,500.00View SEC Filing  
8/14/2015Thomas K EquelsCFOBuy79,104$0.18$14,238.72View SEC Filing  
4/28/2015William A CarterCEOBuy100,000$0.24$24,000.00View SEC Filing  
4/27/2015Thomas K EquelsCFOBuy100,000$0.24$24,000.00View SEC Filing  
4/21/2015William A CarterCEOBuy100,000$0.24$24,000.00View SEC Filing  
4/20/2015Thomas K EquelsCFOBuy100,000$0.24$24,000.00View SEC Filing  
4/17/2015William A CarterCEOBuy73,681$0.23$16,946.63View SEC Filing  
4/16/2015William A CarterCEOBuy26,319$0.23$6,053.37View SEC Filing  
4/15/2015Thomas K EquelsCFOBuy100,000$0.23$23,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Hemispherx BioPharma (NYSE:HEB)
DateHeadline
finance.yahoo.com logoHemispherx Biopharma to Present Data on the Activity of Ampligen® Against Cancer at CHI’s 4th Annual Immuno-Oncology Summit, August 29 through September 2, 2016 in Boston, MA (NYSE:HEB)
finance.yahoo.com - August 29 at 5:18 PM
publicnow.com logoHemispherx Biopharma to Present Data on the Activity of Ampligen® Against Cancer at CHI's 4th Annual Immuno-Oncology Summit, August 29 through September 2, 2016 in Boston, MA (NYSE:HEB)
www.publicnow.com - August 29 at 5:18 PM
News IconHemispherx Biopharma to Present Data on the Activity of Ampligen® Against Cancer at CHI’s 4th Annual Immuno-Oncology Summit, August 29 through… (NYSE:HEB)
forextv.com - August 29 at 9:57 AM
biz.yahoo.com logoSplits Calendar: Hemispherx Biopharma splits before market open today (1:12 ratio) (NYSE:HEB)
biz.yahoo.com - August 29 at 9:57 AM
News IconFirst Product Approved for ME/CFS Indication Anywhere in the World (NYSE:HEB)
www.investorideas.com - August 26 at 5:15 PM
rttnews.com logoHemispherx Announces Approval For Commercial Sale Of Rintatolimod In Argentine (NYSE:HEB)
www.rttnews.com - August 25 at 10:25 AM
4-traders.com logoHemispherx Biopharma Announces Major Breakthrough: Approval for Commercial Sale of Rintatolimod... (NYSE:HEB)
www.4-traders.com - August 25 at 10:25 AM
News IconVolatile Movements - Cisco Systems (NASDAQ:CSCO), Hemispherx BioPharma (NYSEMKT:HEB) - Money News (press release) (NYSE:HEB)
www.newsismoney.com - August 24 at 5:16 PM
News IconTime To Put On The Watch List? - Hemispherx Biopharma, Inc. (NYSEMKT:HEB), Keryx Biopharmaceuticals Inc ... - The Voice Registrar (NYSE:HEB)
voiceregistrar.com - August 24 at 5:16 PM
News IconHemispherx Biopharma, Inc.'s (HEB): See the most Active Stock of Market - Hot Stocks Point (NYSE:HEB)
www.hotstockspoint.com - August 24 at 8:31 AM
smarteranalyst.com logoStock Update (NYSEMKT:HEB): Hemispherx BioPharma, Inc Announces Approval of Rintatolimod in the Argentine ... - Smarter Analyst (NYSE:HEB)
www.smarteranalyst.com - August 24 at 8:31 AM
streetinsider.com logoHemispherx Biopharma (HEB) Receives ANMAT Approval for Commercial Sale of Rintatolimod in Argentine Republic (NYSE:HEB)
www.streetinsider.com - August 23 at 5:35 PM
nasdaq.com logoHemispherx Biopharma Announces Major Breakthrough: Approval for Commercial Sale of Rintatolimod (U. (NYSE:HEB)
www.nasdaq.com - August 23 at 9:47 AM
publicnow.com logoHemispherx Biopharma Announces Major Breakthrough: Approval for Commercial Sale of Rintatolimod (U.S. Tradename: Ampligen®) to Treat Severe Cases of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) in the Argentine Republic (NYSE:HEB)
www.publicnow.com - August 23 at 9:47 AM
biz.yahoo.com logoHEMISPHERX BIOPHARMA INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NYSE:HEB)
biz.yahoo.com - August 20 at 9:36 AM
globenewswire.com logoHemispherx Biopharma Forms Scientific Advisory Board to Provide Additional Scientific and Pharmaceutical Expertise (NYSE:HEB)
globenewswire.com - August 19 at 5:22 PM
4-traders.com logoHemispherx Biopharma : Announces 1-for-12 Reverse Stock Split (NYSE:HEB)
www.4-traders.com - August 18 at 5:24 PM
bizjournals.com logoHemispherx stockholders approve reverse stock split (NYSE:HEB)
www.bizjournals.com - August 18 at 5:24 PM
News IconActive biotech company shares in the news: Hemispherx Biopharma ... - The Voice Registrar (NYSE:HEB)
voiceregistrar.com - August 18 at 8:25 AM
publicnow.com logoHemispherx Biopharma Announces 1-for-12 Reverse Stock Split (NYSE:HEB)
www.publicnow.com - August 17 at 5:38 PM
biz.yahoo.com logoHEMISPHERX BIOPHARMA INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders, Other Events (NYSE:HEB)
biz.yahoo.com - August 17 at 5:38 PM
rttnews.com logoEARNINGS SUMMARY: Details of Hemispherx Biopharma, Inc. Q2 Earnings Report (NYSE:HEB)
www.rttnews.com - August 16 at 8:46 AM
finance.yahoo.com logoHemispherx Biopharma Conducts an Interview with The Wall Street Transcript (NYSE:HEB)
in.finance.yahoo.com - August 15 at 5:36 PM
biz.yahoo.com logoHEMISPHERX BIOPHARMA INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, (NYSE:HEB)
biz.yahoo.com - August 15 at 5:36 PM
publicnow.com logoHemispherx Biopharma Announces Financial Results for the Six Months Ended June 30, 2016 (NYSE:HEB)
www.publicnow.com - August 15 at 5:36 PM
News IconAnalyst Research and Ratings: Hemispherx Biopharma, Inc. (NYSEMKT:HEB), Twitter, Inc. (NYSE:TWTR) - TWN (NYSE:HEB)
thewellesleysnews.com - August 7 at 5:10 PM
News IconBiotech Stocks To Put On Your Watch List: Hemispherx Biopharma, Inc. (NYSEMKT:HEB), Sangamo Biosciences Inc ... - The Voice Registrar (NYSE:HEB)
voiceregistrar.com - August 5 at 5:31 PM
News IconEarnings Estimates Highlight: Royal Caribbean Cruises Ltd. (NYSE:RCL), Hemispherx Biopharma, Inc. (NYSEMKT:HEB) - News Oracle (NYSE:HEB)
www.newsoracle.com - August 5 at 5:31 PM
streetupdates.com logoInvestors Checklist Stocks: Hemispherx BioPharma, Inc. (NYSEMKT:HEB) , Sanofi (NYSE:SNY) - Street Updates (NYSE:HEB)
www.streetupdates.com - August 5 at 8:20 AM
News IconIt's Earnings Time: What to Do with Hemispherx Biopharma, Inc. (NYSEMKT:HEB) Stock - The Voice Registrar (NYSE:HEB)
voiceregistrar.com - August 4 at 8:21 AM
streetupdates.com logoInvestors Reviewing Stocks: Horizon Pharma plc (NASDAQ:HZNP) , Hemispherx BioPharma, Inc. (NYSEMKT:HEB) - Street Updates (NYSE:HEB)
www.streetupdates.com - August 3 at 8:32 AM
streetupdates.com logoInvestors Spotlight: Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) , Hemispherx BioPharma, Inc. (NYSEMKT:HEB) - Street Updates (NYSE:HEB)
www.streetupdates.com - August 1 at 10:09 AM
News IconEarnings Estimates Highlight: CommScope Holding Company, Inc. (NASDAQ:COMM), Hemispherx Biopharma, Inc ... - News Oracle (NYSE:HEB)
www.newsoracle.com - July 29 at 12:34 PM
streetupdates.com logoStocks Movements Activity: Anavex Life Sciences Corp (NASDAQ:AVXL) , Hemispherx BioPharma, Inc. (NYSEMKT:HEB) - Street Updates (NYSE:HEB)
www.streetupdates.com - July 28 at 9:53 PM
4-traders.com logoHemispherx BioPharma : Announces First Shipment of Rintatolimod (Ampligen) to Early Access Program in Europe (NYSE:HEB)
www.4-traders.com - July 28 at 8:19 AM
publicnow.com logoHemispherx Biopharma Reaches Agreement with Avrio Biopharmaceuticals for the Accelerated Production of Ampligen® (NYSE:HEB)
www.publicnow.com - July 27 at 8:48 AM
finance.yahoo.com logo8:34 am Hemispherx Biopharma reaches an agreement with Avrio Biopharmaceuticals to serve as an additional contract manufacturer of its experimental drug, Ampligen (NYSE:HEB)
finance.yahoo.com - July 27 at 8:34 AM
smarteranalyst.com logoStock Update (NYSE MKT:HEB): Hemispherx BioPharma, Inc Announces First Shipment of Rintatolimod (Ampligen ... - Smarter Analyst (NYSE:HEB)
www.smarteranalyst.com - July 26 at 8:17 AM
kcregister.com logoCitigroup Inc. (NYSE:C) went up 0.39%, Hemispherx Biopharma, Inc. (NYSEMKT:HEB), Preferred Apartment ... - KC Register (NYSE:HEB)
www.kcregister.com - July 25 at 10:01 AM
kcregister.com logoInvestors Are Watching: Hemispherx Biopharma, Inc. (NYSEMKT:HEB), BNC Bancorp (NASDAQ:BNCN), Elmira ... - KC Register (NYSE:HEB)
www.kcregister.com - July 25 at 10:01 AM
publicnow.com logoHemispherx Announces First Shipment of Rintatolimod (Ampligen®) to Early Access Program in Europe (NYSE:HEB)
www.publicnow.com - July 25 at 8:48 AM
News IconHemispherx Biopharma Incorporated (NYSEMKT:HEB) Shorts Decreased by 0.34% After Short Covering - Press Telegraph (NYSE:HEB)
presstelegraph.com - July 20 at 9:43 PM
news.cmlviz.com logoHemispherx Biopharma Inc Stock Technicals Hit Strength - CML News (NYSE:HEB)
news.cmlviz.com - July 20 at 3:21 PM
finance.yahoo.com logoHemispherx Biopharma Bolsters Manufacturing and Scientific Capabilities Through Key Consulting and Management Appointments (NYSE:HEB)
finance.yahoo.com - July 19 at 8:36 AM
News IconHemispherx Biopharma Incorporated (NYSEMKT:HEB) Short Interest Increased By 111.25% - Consumer Eagle (NYSE:HEB)
www.consumereagle.com - July 15 at 8:32 AM
nasdaq.com logoHemispherx Provides Details Of Strategic Growth Plan, Transparency Commitment (NYSE:HEB)
www.nasdaq.com - July 14 at 5:33 PM
News IconInsider Trading Alert: Hemispherx BioPharma, Inc (NYSEMKT:HEB) - The Voice Registrar (NYSE:HEB)
voiceregistrar.com - July 14 at 8:53 AM
publicnow.com logoHemispherx Outlines Key Elements of Strategic Growth Plan and Commitment to Transparency (NYSE:HEB)
www.publicnow.com - July 14 at 8:38 AM
News IconTracking Unusual Volume on Shares of: Hemispherx Biopharma, Inc. (:HEB) - Engelwood Daily (NYSE:HEB)
www.engelwooddaily.com - July 13 at 8:15 AM
finance.yahoo.com logoHemispherx Updates the Status of the Alferon® Manufacturing Facility - Yahoo Finance (NYSE:HEB)
finance.yahoo.com - July 11 at 10:07 AM

Social

Hemispherx BioPharma (NYSE:HEB) Chart for Tuesday, August, 30, 2016


Last Updated on 8/30/2016 by MarketBeat.com Staff